These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

982 related articles for article (PubMed ID: 18347167)

  • 41. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
    Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
    Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.
    Rikimaru T; Taketomi A; Yamashita Y; Shirabe K; Hamatsu T; Shimada M; Maehara Y
    Oncology; 2007; 72(1-2):69-74. PubMed ID: 18004079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isoform-specific histone deacetylase inhibitors: the next step?
    Balasubramanian S; Verner E; Buggy JJ
    Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased expression of histone deacetylase 2 is found in human gastric cancer.
    Song J; Noh JH; Lee JH; Eun JW; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Nam SW
    APMIS; 2005 Apr; 113(4):264-8. PubMed ID: 15865607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.
    Campos B; Bermejo JL; Han L; Felsberg J; Ahmadi R; Grabe N; Reifenberger G; Unterberg A; Herold-Mende C
    Cancer Sci; 2011 Feb; 102(2):387-92. PubMed ID: 21143702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
    Atadja P
    Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
    Kim JC; Shin ES; Kim CW; Roh SA; Cho DH; Na YS; Kim TW; Kim MB; Hyun YL; Ro S; Kim SY; Kim YS
    Anticancer Res; 2009 Aug; 29(8):3027-34. PubMed ID: 19661311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
    Sekhavat A; Sun JM; Davie JR
    Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HDAC family: What are the cancer relevant targets?
    Witt O; Deubzer HE; Milde T; Oehme I
    Cancer Lett; 2009 May; 277(1):8-21. PubMed ID: 18824292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.
    Gregoretti IV; Lee YM; Goodson HV
    J Mol Biol; 2004 Apr; 338(1):17-31. PubMed ID: 15050820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
    Fakhry H; Miyamoto T; Kashima H; Suzuki A; Ke H; Konishi I; Shiozawa T
    Hum Pathol; 2010 Jun; 41(6):848-58. PubMed ID: 20178884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
    Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.
    Wagner S; Roemer K
    Biochem Pharmacol; 2005 Apr; 69(7):1059-67. PubMed ID: 15763542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
    Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The molecular mechanism of HDAC inhibitors in anticancer effects.
    Bi G; Jiang G
    Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
    Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
    J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.
    Wu LM; Yang Z; Zhou L; Zhang F; Xie HY; Feng XW; Wu J; Zheng SS
    PLoS One; 2010 Dec; 5(12):e14460. PubMed ID: 21206745
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
    Yasukawa K; Sawamura D; Goto M; Nakamura H; Shimizu H
    Br J Dermatol; 2007 Oct; 157(4):662-9. PubMed ID: 17711521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.